285 related articles for article (PubMed ID: 37452860)
1. Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities.
Rudd SG
Cancer Chemother Pharmacol; 2023 Oct; 92(4):241-251. PubMed ID: 37452860
[TBL] [Abstract][Full Text] [Related]
2. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
3. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
4. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment.
Ma J; Waxman DJ
Mol Cancer Ther; 2008 Dec; 7(12):3670-84. PubMed ID: 19074844
[TBL] [Abstract][Full Text] [Related]
5. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
6. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
7. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
8. Capsaicinoids enhance chemosensitivity to chemotherapeutic drugs.
Friedman JR; Richbart SD; Merritt JC; Perry HE; Brown KC; Akers AT; Nolan NA; Stevenson CD; Hurley JD; Miles SL; Tirona MT; Valentovic MA; Dasgupta P
Adv Cancer Res; 2019; 144():263-298. PubMed ID: 31349900
[TBL] [Abstract][Full Text] [Related]
9. AMCP Partnership Forum: Driving Value and Outcomes in Oncology.
J Manag Care Spec Pharm; 2017 May; 23(5):591-597. PubMed ID: 28448782
[TBL] [Abstract][Full Text] [Related]
10. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
11. American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases.
Artz AS; Somerfield MR; Feld JJ; Giusti AF; Kramer BS; Sabichi AL; Zon RT; Wong SL
J Clin Oncol; 2010 Jul; 28(19):3199-202. PubMed ID: 20516452
[TBL] [Abstract][Full Text] [Related]
12. Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system.
Babiker HM; McBride A; Newton M; Boehmer LM; Drucker AG; Gowan M; Cassagnol M; Camenisch TD; Anwer F; Hollands JM
Crit Rev Oncol Hematol; 2018 Jun; 126():186-200. PubMed ID: 29759560
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological Targeting of Cell Cycle, Apoptotic and Cell Adhesion Signaling Pathways Implicated in Chemoresistance of Cancer Cells.
Alimbetov D; Askarova S; Umbayev B; Davis T; Kipling D
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29882812
[TBL] [Abstract][Full Text] [Related]
14. Death receptor signaling in cancer therapy.
Fulda S; Debatin KM
Curr Med Chem Anticancer Agents; 2003 Jul; 3(4):253-62. PubMed ID: 12769771
[TBL] [Abstract][Full Text] [Related]
15. Targeting pan-essential genes in cancer: Challenges and opportunities.
Chang L; Ruiz P; Ito T; Sellers WR
Cancer Cell; 2021 Apr; 39(4):466-479. PubMed ID: 33450197
[TBL] [Abstract][Full Text] [Related]
16. Mitocans: mitochondrial targeted anti-cancer drugs as improved therapies and related patent documents.
Ralph SJ; Low P; Dong L; Lawen A; Neuzil J
Recent Pat Anticancer Drug Discov; 2006 Nov; 1(3):327-46. PubMed ID: 18221044
[TBL] [Abstract][Full Text] [Related]
17. Discovery of small molecule cancer drugs: successes, challenges and opportunities.
Hoelder S; Clarke PA; Workman P
Mol Oncol; 2012 Apr; 6(2):155-76. PubMed ID: 22440008
[TBL] [Abstract][Full Text] [Related]
18. Cancer-Related Systemic Inflammation: The Challenges and Therapeutic Opportunities for Personalized Medicine.
Shinko D; Diakos CI; Clarke SJ; Charles KA
Clin Pharmacol Ther; 2017 Oct; 102(4):599-610. PubMed ID: 28699186
[TBL] [Abstract][Full Text] [Related]
19. Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets.
Mottini C; Napolitano F; Li Z; Gao X; Cardone L
Semin Cancer Biol; 2021 Jan; 68():59-74. PubMed ID: 31562957
[TBL] [Abstract][Full Text] [Related]
20. Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development.
Stahel R; Bogaerts J; Ciardiello F; de Ruysscher D; Dubsky P; Ducreux M; Finn S; Laurent-Puig P; Peters S; Piccart M; Smit E; Sotiriou C; Tejpar S; Van Cutsem E; Tabernero J
Cancer Treat Rev; 2015 Feb; 41(2):129-35. PubMed ID: 25533737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]